Skip to main content
Journal cover image

Infant HIV type 1 gp120 vaccination elicits robust and durable anti-V1V2 immunoglobulin G responses and only rare envelope-specific immunoglobulin A responses.

Publication ,  Journal Article
Fouda, GG; Cunningham, CK; McFarland, EJ; Borkowsky, W; Muresan, P; Pollara, J; Song, LY; Liebl, BE; Whitaker, K; Shen, X; Vandergrift, NA ...
Published in: J Infect Dis
February 15, 2015

BACKGROUND: Infant responses to vaccines can be impeded by maternal antibodies and immune system immaturity. It is therefore unclear whether human immunodeficiency virus type 1 (HIV-1) vaccination would elicit similar responses in adults and infants. METHOD: HIV-1 Env-specific antibody responses were evaluated in 2 completed pediatric vaccine trials. In the Pediatric AIDS Clinical Trials Group (PACTG) 230 protocol, infants were vaccinated with 4 doses of Chiron rgp120 with MF59 (n=48), VaxGen rgp120 with aluminum hydroxide (alum; n=49), or placebo (n=19) between 0 and 20 weeks of age. In PACTG 326, infants received 4 doses of ALVAC-HIV-1/AIDSVAX B/B with alum (n=9) or placebo (n=13) between 0 and 12 weeks of age. RESULTS: By 52 weeks of age, the majority of maternally acquired antibodies had waned and vaccine Env-specific immunoglobulin G (IgG) responses in vaccinees were higher than in placebo recipients. Chiron vaccine recipients had higher and more-durable IgG responses than VaxGen vaccine recipients or ALVAC/AIDSVAX vaccinees, with vaccine-elicited IgG responses still detectable in 56% of recipients at 2 years of age. Remarkably, at peak immunogenicity, the concentration of anti-V1V2 IgG, a response associated with a reduced risk of HIV-1 acquisition in the RV144 adult vaccine trial, was 22-fold higher in Chiron vaccine recipients, compared with RV144 vaccinees. CONCLUSION: As exemplified by the Chiron vaccine regimen, vaccination of infants against HIV-1 can induce robust, durable Env-specific IgG responses, including anti-V1V2 IgG.

Duke Scholars

Altmetric Attention Stats
Dimensions Citation Stats

Published In

J Infect Dis

DOI

EISSN

1537-6613

Publication Date

February 15, 2015

Volume

211

Issue

4

Start / End Page

508 / 517

Location

United States

Related Subject Headings

  • Retrospective Studies
  • Microbiology
  • Infant, Newborn
  • Infant
  • Immunoglobulin G
  • Immunoglobulin A
  • Humans
  • HIV-1
  • HIV Infections
  • HIV Envelope Protein gp120
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Fouda, G. G., Cunningham, C. K., McFarland, E. J., Borkowsky, W., Muresan, P., Pollara, J., … Permar, S. R. (2015). Infant HIV type 1 gp120 vaccination elicits robust and durable anti-V1V2 immunoglobulin G responses and only rare envelope-specific immunoglobulin A responses. J Infect Dis, 211(4), 508–517. https://doi.org/10.1093/infdis/jiu444
Fouda, Genevieve G., Coleen K. Cunningham, Elizabeth J. McFarland, William Borkowsky, Petronella Muresan, Justin Pollara, Lin Ye Song, et al. “Infant HIV type 1 gp120 vaccination elicits robust and durable anti-V1V2 immunoglobulin G responses and only rare envelope-specific immunoglobulin A responses.J Infect Dis 211, no. 4 (February 15, 2015): 508–17. https://doi.org/10.1093/infdis/jiu444.
Fouda GG, Cunningham CK, McFarland EJ, Borkowsky W, Muresan P, Pollara J, et al. Infant HIV type 1 gp120 vaccination elicits robust and durable anti-V1V2 immunoglobulin G responses and only rare envelope-specific immunoglobulin A responses. J Infect Dis. 2015 Feb 15;211(4):508–17.
Fouda, Genevieve G., et al. “Infant HIV type 1 gp120 vaccination elicits robust and durable anti-V1V2 immunoglobulin G responses and only rare envelope-specific immunoglobulin A responses.J Infect Dis, vol. 211, no. 4, Feb. 2015, pp. 508–17. Pubmed, doi:10.1093/infdis/jiu444.
Fouda GG, Cunningham CK, McFarland EJ, Borkowsky W, Muresan P, Pollara J, Song LY, Liebl BE, Whitaker K, Shen X, Vandergrift NA, Overman RG, Yates NL, Moody MA, Fry C, Kim JH, Michael NL, Robb M, Pitisuttithum P, Kaewkungwal J, Nitayaphan S, Rerks-Ngarm S, Liao H-X, Haynes BF, Montefiori DC, Ferrari G, Tomaras GD, Permar SR. Infant HIV type 1 gp120 vaccination elicits robust and durable anti-V1V2 immunoglobulin G responses and only rare envelope-specific immunoglobulin A responses. J Infect Dis. 2015 Feb 15;211(4):508–517.
Journal cover image

Published In

J Infect Dis

DOI

EISSN

1537-6613

Publication Date

February 15, 2015

Volume

211

Issue

4

Start / End Page

508 / 517

Location

United States

Related Subject Headings

  • Retrospective Studies
  • Microbiology
  • Infant, Newborn
  • Infant
  • Immunoglobulin G
  • Immunoglobulin A
  • Humans
  • HIV-1
  • HIV Infections
  • HIV Envelope Protein gp120